Biogen (LTS:0R1B) E10: $19.63 (As of Mar. 2026)


LTS:0R1B Biogen Inc LTS:0R1B
76 GF Score
Price $214.54
GF Value $187.44
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Biogen E10?

Biogen LTS:0R1B +2.31% 76 E10 is $19.63 as of Mar. 2026. GuruFocus rates LTS:0R1B with a GF Score™ of 76/100 and a GF Value™ of $187.44 (Modestly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Biogen's adjusted earnings per share data for the three months ended in Mar. 2026 was $2.150. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $19.63 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Biogen's average E10 Growth Rate was -3.10% per year. During the past 3 years, the average E10 Growth Rate was -0.20% per year. During the past 5 years, the average E10 Growth Rate was 4.70% per year. During the past 10 years, the average E10 Growth Rate was 13.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Biogen was 186.40% per year. The lowest was -64.80% per year. And the median was 35.00% per year.

As of today (2026-07-03), Biogen's current stock price is $214.54. Biogen's E10 for the quarter that ended in Mar. 2026 was $19.63. Biogen's Shiller PE Ratio of today is 10.93.

During the past 13 years, the highest Shiller PE Ratio of Biogen was 41.15. The lowest was 5.56. And the median was 16.27.


Biogen  (LTS:0R1B) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Biogen's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=214.54/19.63
=10.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Biogen was 41.15. The lowest was 5.56. And the median was 16.27.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Biogen E10 Related Terms


Biogen E10 Historical Data

* Premium members only.

The historical data trend for Biogen's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen E10 Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.87 19.95 20.66 20.60 20.22

Biogen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.60 20.59 20.77 20.22 19.63

LTS:0R1B vs OGN, AMRN, SCLX: E10 Comparison

For the Drug Manufacturers - General subindustry, Biogen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Shiller PE Ratio falls into.


LTS:0R1B
76GF Score
Biogen Inc LTS:0R1B
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.15/330.2130*330.2130
=2.150

Current CPI (Mar. 2026) = 330.2130.

Biogen Quarterly Data

per share eps CPI Adj_EPS
201606 4.790 241.018 6.563
201609 4.710 241.428 6.442
201612 2.990 241.432 4.090
201703 3.460 243.801 4.686
201706 4.070 244.955 5.487
201709 5.790 246.819 7.746
201712 -1.410 246.524 -1.889
201803 5.540 249.554 7.331
201806 4.180 251.989 5.478
201809 7.150 252.439 9.353
201812 4.730 251.233 6.217
201903 7.150 254.202 9.288
201906 7.850 256.143 10.120
201909 8.390 256.759 10.790
201912 8.080 256.974 10.383
202003 8.080 258.115 10.337
202006 9.590 257.797 12.284
202009 4.460 260.280 5.658
202012 2.320 260.474 2.941
202103 2.690 264.877 3.354
202106 2.990 271.696 3.634
202109 2.220 274.310 2.672
202112 2.500 278.802 2.961
202203 2.060 287.504 2.366
202206 7.240 296.311 8.068
202209 7.840 296.808 8.722
202212 3.790 296.797 4.217
202303 2.670 301.836 2.921
202306 4.070 305.109 4.405
202309 -0.470 307.789 -0.504
202312 1.710 306.746 1.841
202403 2.700 312.332 2.855
202406 4.000 314.175 4.204
202409 2.660 315.301 2.786
202412 1.830 315.605 1.915
202503 1.640 319.799 1.693
202506 4.330 322.561 4.433
202509 3.170 324.800 3.223
202512 -0.330 324.054 -0.336
202603 2.150 330.213 2.150

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $19.63 mean?
Biogen (LTS:0R1B) has a E10 of $19.63 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Biogen and its competitors.
Is Biogen's E10 too high?
Biogen's current E10 is $19.63. Overall, Biogen has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogen's E10 compare to OGN and AMRN?
Biogen's E10 of $19.63 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Biogen and its competitors. Biogen's current E10 is $19.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (LTS:0R1B) is currently considered Modestly Overvalued. The stock's GF Value™ is $187.44, compared to a current price of $214.54 — trading 14.5% above its estimated fair value. The current E10 is $19.63. Biogen's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Biogen (LTS:0R1B), the current E10 is $19.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (LTS:0R1B) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of $214.54 is trading 14.5% above its estimated GF Value™ of $187.44. GuruFocus considers Biogen to be Modestly Overvalued.

Key valuation signals for LTS:0R1B:

  • E10: $19.63
  • GF Value™: $187.44 vs. price of $214.54 (14.5% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the LTS:0R1B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
76GF Score

Get the complete analysis for LTS:0R1B

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$214.54
Price
$187.44
GF Value